The evidence that stimulation via BcR is one of the driving forces for CLL cell expansion promoted the screening of a variety of TKIs capable of blocking BcR-dependent signaling, with potential therapeutic value. Here, BCR is linked to B-cell chronic lymphocytic leukemia.